- Home
- About
- Contact
- Management
- Technology
- Media
- Press Release 06/19/18
- 7 Hills Pharma Announces Scientific Advisory Board Formed With Prominent Immuno-Oncology Experts to Help Advance Novel Integrin Activator Program
- 7 Hills Pharma Appoints Lionel D. Lewis As Chief Medical Officer
- 7 Hills Pharma Announces FDA Clearance of Investigational New Drug Application for 7HP349, a First-in-Class Immune Stimulant
- 7 Hills Pharma Announces Coronavirus Vaccine Program Targeting At-Risk Elderly
- 7 Hills Pharma Announces Coronavirus Vaccine Program Targeting At-Risk Elderly
- 7 Hills Pharma to Deliver Video Presentation At BIO Digital 2020 June 8 – 12
- 7 Hills Pharma Receives $3.5M to Continue Development Of Integrin Activators to Augment Immunotherapies
- 7 Hills Pharma Highlights Cell Adhesion
- 7 Hills Pharma Announces Positive Data With Oral Immunostimulant to Improve Effectiveness of COVID-19 Vaccines
- 7 Hills Pharma Awarded Pioneering Patent Estate Covering Integrin Activators to Improve Effectiveness of Immunotherapies
- Opinion: Warp Speed to a united or divided America? COVID-19 vaccine trials must include at-risk groups
- 7 Hills Pharma to Participate in Johnson & Johnson Innovation’s BLUE KNIGHT™ Collaboration with U.S. Government for its Efforts to Combat COVID-19
- BARDA enlisting start-ups in fight against COVID-19 via JLABS collaboration
- 7 Hills Pharma Receives $2M SBIR Grant from NCI to Launch Phase 1 Trials of Lead Immunostimulant to Augment Immuno-Oncology Drugs, COVID-19 and Flu Vaccines
- 7 Hill Pharma Names William Schary VP of Clinical & Regulatory Affairs
- 7 Hills Pharma Announces First Healthy Volunteers Dosed In Landmark Phase 1 Trial of Immunostimulant to Improve Immuno-Oncology Drugs COVID-19 and Influenza Vaccines
- 7 Hills Pharma Receives Orphan Drug Designation for Lead Product, 7HP349, in Treatment of Malignant Melanoma
- 7 Hills Pharma CEO Cites Seniors’ Weakened Immune Systems as Challenge for COVID-19 Vaccines’ Effectiveness
- Two Incentives that Could Open the Floodgates to Drug Repositioning for COVID-19
- 7 Hills Pharma Names Biopharma Industry Veteran Michael S. Perry Chairman of its Board of Managers
- Scientific Advisory Board
- Corporate Board
- Management
- Leadership
- Publications
- SAB - with Dr. Humphrey
- 7 Hills Pharma Surpasses $25MM Milestone in Nondilutive Funding
- Home
- About
- Contact
- Management
- Technology
- Media
- Press Release 06/19/18
- 7 Hills Pharma Announces Scientific Advisory Board Formed With Prominent Immuno-Oncology Experts to Help Advance Novel Integrin Activator Program
- 7 Hills Pharma Appoints Lionel D. Lewis As Chief Medical Officer
- 7 Hills Pharma Announces FDA Clearance of Investigational New Drug Application for 7HP349, a First-in-Class Immune Stimulant
- 7 Hills Pharma Announces Coronavirus Vaccine Program Targeting At-Risk Elderly
- 7 Hills Pharma Announces Coronavirus Vaccine Program Targeting At-Risk Elderly
- 7 Hills Pharma to Deliver Video Presentation At BIO Digital 2020 June 8 – 12
- 7 Hills Pharma Receives $3.5M to Continue Development Of Integrin Activators to Augment Immunotherapies
- 7 Hills Pharma Highlights Cell Adhesion
- 7 Hills Pharma Announces Positive Data With Oral Immunostimulant to Improve Effectiveness of COVID-19 Vaccines
- 7 Hills Pharma Awarded Pioneering Patent Estate Covering Integrin Activators to Improve Effectiveness of Immunotherapies
- Opinion: Warp Speed to a united or divided America? COVID-19 vaccine trials must include at-risk groups
- 7 Hills Pharma to Participate in Johnson & Johnson Innovation’s BLUE KNIGHT™ Collaboration with U.S. Government for its Efforts to Combat COVID-19
- BARDA enlisting start-ups in fight against COVID-19 via JLABS collaboration
- 7 Hills Pharma Receives $2M SBIR Grant from NCI to Launch Phase 1 Trials of Lead Immunostimulant to Augment Immuno-Oncology Drugs, COVID-19 and Flu Vaccines
- 7 Hill Pharma Names William Schary VP of Clinical & Regulatory Affairs
- 7 Hills Pharma Announces First Healthy Volunteers Dosed In Landmark Phase 1 Trial of Immunostimulant to Improve Immuno-Oncology Drugs COVID-19 and Influenza Vaccines
- 7 Hills Pharma Receives Orphan Drug Designation for Lead Product, 7HP349, in Treatment of Malignant Melanoma
- 7 Hills Pharma CEO Cites Seniors’ Weakened Immune Systems as Challenge for COVID-19 Vaccines’ Effectiveness
- Two Incentives that Could Open the Floodgates to Drug Repositioning for COVID-19
- 7 Hills Pharma Names Biopharma Industry Veteran Michael S. Perry Chairman of its Board of Managers
- Scientific Advisory Board
- Corporate Board
- Management
- Leadership
- Publications
- SAB - with Dr. Humphrey
- 7 Hills Pharma Surpasses $25MM Milestone in Nondilutive Funding
DEVELOPING NOVEL IMMUNOTHERAPIES FOR THE TREATMENT OF CANCER AND THE PREVENTION OF INFECTIOUS DISEASES
7 Hills Pharma Inc. © 2024